OncLive TV

Paolo Strati, MD, discusses several ongoing investigations aiming to improve upon current immunotherapy combinations, highlighting the introduction of novel regimens into the treatment landscape of follicular lymphoma.

Ajai Chari, MD, discusses the use of the CAR T-cell therapies idecabtagene vicleucel and ciltacabtagene autoleucel in the treatment of patients with multiple myeloma.

Sneha Phadke, DO, MPH, discusses the benefit associated with treatment consisting of the antibody drug conjugates sacituzumab govitecan in hormone receptor-positive/HER2-negative breast cancer.

Marina Sharifi, MD, PhD, discusses the benefit of utilizing personalized and targeted therapy approaches in the treatment of patients with breast cancer.

Courtney DiNardo, MD, MSCE, discusses triplets that serve as alternatives to standard-of-care approaches with azacitidine and venetoclax doublet therapy in select patients with acute myeloid leukemia.

Stephen M. Ansell, MD, PhD, highlights several emerging therapeutics that have the potential to better harness the immune system in patients with lymphoma subtypes.

Farhad Ravandi-Kashani, MD, discusses the FDA approval of luspatercept in myelodysplastic syndrome.

John Seymour, MBBS, FRACP, PhD, discusses the importance of targeted therapy in patients with chronic lymphocytic leukemia.

Clara Hwang, MD, discusses unmet needs in patients with nonmetastatic prostate cancer who then progress on novel agents and develop metastatic disease.

Ajai Chari, MD, discusses important patient factors to consider when selecting between currently approved BCMA-targeted therapies for the treatment of patients with multiple myeloma.

Jason R. Westin, MD, director, discusses how the approval of CAR T-cell therapies in the second-line setting has radically shifted preferred treatment approaches in relapsed/refractory large B-cell lymphoma.

Experts discuss the challenges of the ongoing cisplatin and carboplatin shortages in the United States and detail how they are adapting in their practices.

Inderjit Mehmi, MD, medical oncologist, discusses the rationale for investigating the combination of fianlimab and cemiplimab in patients who have advanced melanoma with poor-risk features

Sneha Phadke, DO, MPH, discusses sequencing treatment with antibody drug conjugates in hormone receptor-positive/HER2-negative breast cancer, as well as questions remaining within this space.

Guillermo Garcia-Manero, MD, discusses the investigation of luspatercept vs epoetin alfa in patients with erythropoiesis-stimulating agent-naïve, lower-risk myelodysplastic syndromes and disease-related anemia who requires red blood cell transfusions.

Marwan G. Fakih, MD, expands on long-term findings from the phase 2/3 PROSPECT trial and how these findings may influence the optimal use of nonoperative management strategies in locally advanced rectal cancer.

Paul G. Richardson, MD, discusses how the continued development of the novel agent mezigdomide could affect the treatment paradigm for patients who progressed on, and developed resistance to, other available BCMA-directed therapies.

Natasha B. Leighl, BSc, MMSc, MD, discusses efficacy findings with the EGFR/MET inhibitor amivantamab in patients with advanced non–small cell lung cancer harboring MET exon 14 skipping mutations.

Ticiana Leal, MD, discusses the rationale for and findings from a PD-L1 subgroup analysis of the phase 3 LUNAR trial in patients with metastatic non–small cell lung cancer.

Marcelo Vailati Negrao, MD, discusses efficacy findings from the phase 1b/2 KontRASt-01 trial (NCT04699188) in patients with KRAS G12C–mutated solid tumors.

Shirish M. Gadgeel, MD, discusses 2-year follow-up data from the phase 1/2 KRYSTAL-1 trial in patients with advanced or metastatic non–small cell lung cancer harboring KRAS G12C mutations.

John Seymour, MBBS, FRACP, PhD, discusses the curative potential of fludarabine, cyclophosphamide, and rituximab in patients with chronic lymphocytic leukemia.

Marisol Miranda-Galvis, DDS, MS, PhD, discusses the investigation of disparities in survival outcomes of patients with hematologic malignancies relating to social determinants.

Anthony M Hunter, MD, discusses the current treatment landscape with JAK inhibitors in myelofibrosis.

Luciano J. Costa, MD, PhD, discusses clinical implications derived from a final analysis of the phase 2 MASTER trial, which evaluated quadruplet induction therapy in multiple myeloma.

Joshi Alumkal, MD, discusses treatment options for patients with metastatic castrate-resistant prostate cancer harboring homologous recombination deficient alterations, including PARP inhibitors.

David Harpole, MD, discusses findings from an exploratory analysis of the phase 3 AEGEAN trial in patients with EGFR-mutated non–small cell lung cancer.

Pasi A. Jänne, MD, PhD, discusses findings from the phase 3 FLAURA2 trial in patients with EGFR-mutant non–small cell lung cancer.

Guillermo Garcia-Manero, MD, discusses the key efficacy findings from the phase 3 COMMANDS trial evaluating luspatercept-aamt in patients with myelodysplastic syndrome who were erythropoiesis-stimulating agent naïve and red blood cell transfusion dependent.

Harry Erba, MD, PhD, discusses the role of quizartinib for the treatment of newly diagnosed patients with FLT3-ITD–positive acute myeloid leukemia.